One of the major issues against the use of muscarinic antagonists or dopamine agonist eyedrops for the controlling of eye growth and prevention of myopia is the unacceptable rate of iatrogenic conjunctivitis or dermatitis. This invention relates to the association of those active principles with an antiallergic component. In alternative the ophthalmic use of a molecule that simultaneously has an antimuscarinic and/or dopaminergic action along with an antihistaminic function.
